Sunday , 24 September 2017

Home » RESOURCES » INVESTING » Gilead shares slip as jury sides with Merck in patent lawsuit

Gilead shares slip as jury sides with Merck in patent lawsuit

Shares of Gilead Sciences Inc. slipped while Merck & Co. rose in the extended session Thursday after a jury awarded Merck billions in royalties over a hepatitis C drug dispute. In a patent lawsuit against Gilead, a federal jury in Delaware awarded Merck $2.54 billion in royalties over Gilead’s Sovaldi and Harvoni hepatitis C drugs, according to Reuters. Gilead shares fell 1.9% to $74.12, while Merck shares advanced 1.2% to $63.10 after hours.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Gilead shares slip as jury sides with Merck in patent lawsuit Reviewed by on . Shares of Gilead Sciences Inc. slipped while Merck & Co. rose in the extended session Thursday after a jury awarded Merck billions in royalties over a hepat Shares of Gilead Sciences Inc. slipped while Merck & Co. rose in the extended session Thursday after a jury awarded Merck billions in royalties over a hepat Rating:
scroll to top